ARTIGOS CIENTÍFICOS

1. Langer, B., Wolosker, M.Coagulação e brinólise: ideias atuais e suas aplicações clínicas. RevMed (São Paulo). 2006 out.-dez.;85(4).


2. Franco, R.F. Fisiologia da coagulação, anticoagulação e brinólise. Medicina, RibeirãoPreto, 34:
229-237, jul./dez. 2001.


3. Zu, X., et al. Thrombolytic Activities of Nattokinase Extracted from BacillusSubtilis Fermented
Soybean Curd Residues. International Journal of Biology Vol. 2, No. 2; July 2010.


4. Pais, E., Alexy, T., Holsworth, R.E., Meiselman, H.J. Eects of nattokinase, a pro-brinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc 2006; 35(1-2):139-42.


5. Yin, L.J., Lin, H.H., Jiang, S.T.Bioproperties of potent nattokinase from Bacillus subtilis YJ1.J Agric Food Chem. 2010 May 12;58(9):5737-42.


6. Yin, L.J., Lin, H.H., Jiang, S.T.Bioproperties of potent nattokinase from Bacillus subtilis YJ1.J Agric Food Chem. 2010 May 12;58(9):5737-42.


7. 7Zoccali, C., Mallamaci, F., Tripepi, G., Cutrupi, S., Parlongo, S., Malatino, L.S., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Stancanelli, B., Nicocia, G., Buemi, M. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure.J Intern Med. 2003 Aug;254(2):132-9.


8. F., Fatuzzo, P., Seminara, G., Stancanelli, B., Nicocia, G., Buemi, M. Fibrinogen, mortality and incidentcardiovascular complications in end-stage renal failure.J Intern Med. 2003 Aug;254(2):132-9.


9. Urano, T., Ihara, H., Umemura, K., Suzuki, Y., Oike, M., Akita, S., Tsukamoto.Y., Suzuki. I., Takada, A. The probrinolytic enzyme subtilisin NAT puried from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1.J Biol Chem. 2001 Jul 6;276(27):24690-6.


10. Suzuki, Y., Kondo, K., Matsumoto, Y., Zhao, B.Q., Otsuguro, K., Maeda, T., Tsukamoto, Y., Urano T., Umemura, K. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci. 2003. Jul 25;73(10):1289-98.


11. Hsia, C.H., Shen, M.C., Lin, J.S., Wen, Y.K., Hwang, K.L., Cham, T.M., Yang, N.C.Nattokinase decreases plasma levels of brinogen, factor VII, and factor VIII in human subjects.Nutr Res. 2009 Mar;29(3):190-6.


12. Fujita, M., Ohnishi, K., Takaoka, S., Ogasawara, K., Fukuyama, R., Nakamuta, H. Antihypertensive eects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats.Biol Pharm Bull. 2011;34(11):1696-701.


13. Kim, J.Y., Gum, S.N., Paik, J.K., et al. Eects of nattokinase on blood pressure: a randomized,
controlled trial.Hypertens Res. 2008 Aug;31(8):1583-8.


14. Ninomiya, J., Yamada, S .Clinical study of eect and safety of nattokinase administration on
cardiovascular patients with warfarin.Vol. 36, nº 5, pp. 453-464, 2008.


15. Asarone, M. R., et al. Prevention of venous thrombosis in long-haul ights with Flite Tabs:
the lonit-ite rondomized, controlled trial. Angiology. 54(5): 531-539, 2003.